Eflornithine (cancer chemoprevention research context)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-EFLORNITHINE-CHEMOPREVENTION |
|---|---|
| Type | Drug |
| Aliases | DFMODifluoromethylornithineEflornithine (cancer chemoprevention)Iwilfin (oral, neuroblastoma)Ornidyl (IV, trypanosomiasis — discontinued in US)Vaniqa (topical, hirsutism)alpha-DFMOЕфлорнітин (хіміопрофілактика раку — дослідницький контекст) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-COLON-2025 SRC-USPSTF-CRC-2021 |
Drug Facts
| Class | Irreversible ornithine decarboxylase (ODC) inhibitor — polyamine biosynthesis inhibitor |
|---|---|
| Mechanism | Suicide enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (putrescine → spermidine → spermine) biosynthesis. Depletion of polyamines suppresses cell proliferation. Cancer-prevention rationale: ODC is a c-Myc target; polyamines are elevated in colorectal adenomas and many cancers. PACES (Phase III, Meyskens et al.): eflornithine 500 mg + sulindac 150 mg PO daily reduced metachronous adenomas by ~70% over 36 months in patients with prior sporadic colon adenomas (Cancer Prev Res 2008); ongoing follow-up. FDA-approved (Iwilfin, 2024) for maintenance therapy of high-risk neuroblastoma — first oncology indication for the agent. |
| Typical dosing | Cancer-prevention research context (PACES protocol): Eflornithine 500 mg PO daily + sulindac 150 mg PO daily (combination, not monotherapy). Neuroblastoma maintenance (Iwilfin, on-label, separate context): Weight-based; ~750-1500 mg/m² PO BID — see Iwilfin label. Audiometric monitoring: ototoxicity risk; baseline + periodic audiogram. CBC + LFTs periodically. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 chemoprevention-workstream authoring; pending two-Clinical- Co-Lead signoff per CHARTER §6.1 dev-mode. RESEARCH / LIMITED-ACCESS agent. CRC chemoprevention is OFF-LABEL and based on Meyskens PACES trial (Cancer Prev Res 2008): combination with sulindac reduced metachronous adenoma recurrence by ~70% in patients with prior sporadic adenomas; ongoing follow-up in NCI Cancer Prevention Network. Iwilfin (2024 FDA approval) is for high-risk neuroblastoma maintenance, not CRC chemoprevention. Engine should NOT auto-recommend for CRC chemoprevention; reserved for clinical-trial enrollment via NCI CPN or specialized hereditary-CRC centers. Audiometric monitoring required. UA-access very limited.
Used By
No reverse references found in the YAML corpus.